BIO Professional Development
Through a curated network of education alliance partners, BIO offers industry professionals executive training and development resources for accelerating career growth
Drug Discovery of Biologics Primer 201
Drug Discovery of Biologics Primer 201 builds upon the foundational knowledge of Drug Discovery of Biologics Primer 101, focusing on systematic insights into therapeutic antibody discovery. This course begins with the significance of antibody screening and structure-based affinity maturation, emphasizing antibody Chemistry, Manufacturing, and Controls (CMC) liabilities. Covering four therapeutic antibody classes, including immune checkpoint inhibitors, this class showcases the factors that influence early drug candidate selection. The data and transition criteria essential for advancing candidate drugs from the discovery phase to preclinical development are also covered. Enroll today to deepen your therapeutic antibody drug discovery knowledge!
Takeaways
- Master the drug discovery workflow and align specific goals for successful development.
- Analyze the early drug candidate selection criteria and consider therapeutic antibody properties in the selection process.
- Utilize in silicon, in vitro, and in vivo models to investigate functional pharmacological activity.
- Demonstrate proficiency in the drug discovery considerations needed for the four distinct classes of antibody therapeutics.
- Investigate pharmacology data and transition criteria to determine which drug candidates are progressing into preclinical development.
Certificate Requirements
Complete the course quiz with a passing score of 75% or higher